Many cancer drugs approved by the European Medicines Agency (EMA) between 1995 and 2020 lack proof of added benefit, particularly those approved through expedited ("fast track") pathways, finds a study published by The BMJ.
from Medical Xpress - latest medical and health news stories https://ift.tt/oJseCgO
